{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:20:49Z","timestamp":1768004449473,"version":"3.49.0"},"reference-count":140,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T00:00:00Z","timestamp":1539216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>The main indications for antifungal drug administration in pediatrics are reviewed as well as an update of the data of antifungal agents and antifungal policies performed. Specifically, antifungal therapy in three main areas is updated as follows: (a) Prophylaxis of premature neonates against invasive candidiasis; (b) management of candidemia and meningoencephalitis in neonates; and (c) prophylaxis, empiric therapy, and targeted antifungal therapy in children with primary or secondary immunodeficiencies. Fluconazole remains the most frequent antifungal prophylactic agent given to high-risk neonates and children. However, the emergence of fluconazole resistance, particularly in non-albicans Candida species, should be considered during preventive or empiric therapy. In very-low birth-weight neonates, although fluconazole is used as antifungal prophylaxis in neonatal intensive care units (NICU\u2019s) with relatively high incidence of invasive candidiasis (IC), its role is under continuous debate. Amphotericin B, primarily in its liposomal formulation, remains the mainstay of therapy for treating neonatal and pediatric yeast and mold infections. Voriconazole is indicated for mold infections except for mucormycosis in children &gt;2 years. Newer triazoles-such as posaconazole and isavuconazole-as well as echinocandins, are either licensed or under study for first-line or salvage therapy, whereas combination therapy is kept for refractory cases.<\/jats:p>","DOI":"10.3390\/jof4040115","type":"journal-article","created":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T02:58:04Z","timestamp":1539313084000},"page":"115","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Advances in the Treatment of Mycoses in Pediatric Patients"],"prefix":"10.3390","volume":"4","author":[{"given":"Elias","family":"Iosifidis","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, 3rd Department of Pediatrics, Faculty of Medicine, Aristotle University School of Health Sciences, Konstantinoupoleos 49, 54642 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2920-5136","authenticated-orcid":false,"given":"Savvas","family":"Papachristou","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, 3rd Department of Pediatrics, Faculty of Medicine, Aristotle University School of Health Sciences, Konstantinoupoleos 49, 54642 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0202-364X","authenticated-orcid":false,"given":"Emmanuel","family":"Roilides","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, 3rd Department of Pediatrics, Faculty of Medicine, Aristotle University School of Health Sciences, Konstantinoupoleos 49, 54642 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,10,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/jpids\/pix046","article-title":"Epidemiology of Invasive Fungal Disease in Children","volume":"6","author":"Pana","year":"2017","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1517\/14656566.2015.1013936","article-title":"Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients: An update","volume":"16","author":"Pana","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1469-0691.12040","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: Prevention and management of invasive infections in neonates and children caused by Candida spp.","volume":"18","author":"Hope","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QCO.0b013e328343614e","article-title":"Amphotericin B in Neonates: Deoxycholate or Lipid Formulation\u2014What is the Right Choice?","volume":"24","author":"Turkova","year":"2011","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.fgb.2014.10.003","article-title":"Cryptococcosis diagnosis and treatment: What do we know now","volume":"78","author":"Perfect","year":"2015","journal-title":"Fungal Genet. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/00006454-199802000-00013","article-title":"Liposomal amphotericin B treatment for neonatal fungal infections","volume":"17","author":"Scarcella","year":"1998","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/jphp.12878","article-title":"Comprehensive drug utilization review in neonates: Liposomal amphotericin B","volume":"70","author":"Silver","year":"2018","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S1470-2045(14)70017-8","article-title":"Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation","volume":"15","author":"Groll","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1200\/JCO.2016.71.7017","article-title":"Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update","volume":"35","author":"Lehrnbecher","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00431-012-1758-9","article-title":"Antifungal therapy in children: An update","volume":"172","author":"Cecinati","year":"2013","journal-title":"Eur. J. Pediatr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/j.1469-0691.2010.03334.x","article-title":"Update on antifungal agents for paediatric patients","volume":"16","author":"Groll","year":"2010","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12281-014-0175-0","article-title":"Rare fungal infections in children: An updated review of the literature","volume":"8","author":"Pana","year":"2014","journal-title":"Curr. Fungal Infect. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ijantimicag.2006.07.013","article-title":"Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: A 12-year review of serum concentrations from a UK clinical assay reference laboratory","volume":"28","author":"Soltani","year":"2006","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2165\/00148581-200709050-00004","article-title":"Antifungal agents in neonates: Issues and recommendations","volume":"9","author":"Almirante","year":"2007","journal-title":"Paediatr. Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jpeds.2017.02.039","article-title":"Fluconazole Doses Used for Prophylaxis of Invasive Fungal Infection in Neonatal Intensive Care Units: A Network Meta-Analysis","volume":"185","author":"Leonart","year":"2017","journal-title":"J. Pediatr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/pbc.23415","article-title":"Antifungal prophylaxis in pediatric hematology\/oncology: New choices & new data","volume":"59","author":"Dvorak","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJM199203263261301","article-title":"A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation","volume":"326","author":"Goodman","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/infdis\/171.6.1545","article-title":"Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation\u2014A prospective, randomized, double-blind study","volume":"171","author":"Slavin","year":"1995","journal-title":"J. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood.V96.6.2055","article-title":"Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebo-controlled trial","volume":"96","author":"Marr","year":"2000","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/596757","article-title":"Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/pbc.24847","article-title":"Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients","volume":"61","author":"Science","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1128\/AAC.43.8.1955","article-title":"Safety and tolerability of fluconazole in children","volume":"43","author":"Novelli","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/ciu646","article-title":"Prevention of infections during primary immunodeficiency","volume":"59","author":"Aguilar","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/j.1469-0691.2010.03289.x","article-title":"Invasive fungal infections in congenital immunodeficiencies","volume":"16","author":"Antachopoulos","year":"2010","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/petr.12263","article-title":"Antifungal prophylaxis in pediatric lung transplantation: An international multicenter survey","volume":"18","author":"Mead","year":"2014","journal-title":"Pediatr. Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-2141.2005.05727.x","article-title":"Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: A meta-analysis of randomised-controlled trials","volume":"131","author":"Vardakas","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood-2003-08-2644","article-title":"Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants","volume":"103","author":"Marr","year":"2004","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/phar.1829","article-title":"An Optimized Voriconazole Dosing Strategy to Achieve Therapeutic Serum Concentrations in Children Younger than 2 Years Old","volume":"36","author":"Zembles","year":"2016","journal-title":"Pharmacotherapy"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00006454-200203000-00015","article-title":"Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children","volume":"21","author":"Walsh","year":"2002","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10096-010-1123-8","article-title":"Retrospective survey on the off-label use of posaconazole in pediatric hematology patients","volume":"30","author":"Cesaro","year":"2011","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/jcpt.12483","article-title":"Therapeutic drug monitoring of posaconazole oral suspension in paediatric patients younger than 13 years of age: A retrospective analysis and literature review","volume":"42","author":"Jancel","year":"2017","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/INF.0000000000000963","article-title":"Pharmacokinetics of Posaconazole Oral Suspension in Children Dosed According to Body Surface Area","volume":"35","author":"Vanstraelen","year":"2016","journal-title":"Pediatr Infect. Dis. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00432-017-2369-7","article-title":"Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation","volume":"143","author":"Doring","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/14787210.2018.1490177","article-title":"Posaconazole in immunocompromised pediatric patients","volume":"16","author":"Vicenzi","year":"2018","journal-title":"Expert. Rev. Anti Infect. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s40272-016-0211-3","article-title":"Micafungin: A Review in the Prophylaxis and Treatment of Invasive Candida Infections in Paediatric Patients","volume":"19","author":"Scott","year":"2017","journal-title":"Paediatr. Drugs"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1097\/INF.0000000000000434","article-title":"Micafungin in Premature and Non-Premature Infants: A Systematic Review of Nine Clinical Trials","volume":"33","author":"Manzoni","year":"2014","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s10096-005-0024-8","article-title":"International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia","volume":"24","author":"Kontoyiannis","year":"2005","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40262-017-0578-5","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Micafungin","volume":"57","author":"Wasmann","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1086\/524063","article-title":"The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: Implications for echinocandin therapy in neonates","volume":"197","author":"Hope","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1128\/AAC.01679-09","article-title":"Population pharmacokinetics of micafungin in neonates and young infants","volume":"54","author":"Hope","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1111\/bcp.13628","article-title":"Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: A randomized, open-label clinical trial","volume":"84","author":"Leroux","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1093\/jac\/dkw072","article-title":"Shunt lock therapy with micafungin to treat shunt-associated Candida albicans meningitis in an infant","volume":"71","author":"Auriti","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"Ratanatharathorn","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s15010-014-0601-9","article-title":"Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg\/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"42","author":"Yoshikawa","year":"2014","journal-title":"Infection"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1097\/MPH.0b013e318299c6bd","article-title":"Efficacy and safety of micafungin for febrile neutropenia in pediatric patients with hematological malignancies: A multicenter prospective study","volume":"35","author":"Kobayashi","year":"2013","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1586\/eri.11.4","article-title":"Caspofungin therapy in immunocompromised children and neonates","volume":"9","author":"Somer","year":"2011","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_52","first-page":"191","article-title":"Successful caspofungin treatment of persistent candidemia in extreme prematurity at 23 and 24 weeks\u2019 gestation","volume":"113","author":"Jeon","year":"2014","journal-title":"Taiwan Yi Zhi"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1128\/AAC.00868-08","article-title":"Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age","volume":"53","author":"Macias","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1128\/AAC.50.1.143-147.2006","article-title":"Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies","volume":"50","author":"Mattiuzzi","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Doring, M., Hartmann, U., Erbacher, A., Lang, P., Handgretinger, R., and Muller, I. (2012). Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective analysis. BMC Infect. Dis., 12.","DOI":"10.1186\/1471-2334-12-151"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1007\/s12325-017-0534-7","article-title":"Comparison of Efficacy and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis","volume":"34","author":"Maximova","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/CCM.0b013e31826a409c","article-title":"Evaluation of efficacy of probiotics in prevention of candida colonization in a PICU-a randomized controlled trial","volume":"41","author":"Kumar","year":"2013","journal-title":"Crit. Care Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/myc.12021","article-title":"Role of probiotics in prevention of Candida infection in critically ill children","volume":"56","author":"Kumar","year":"2013","journal-title":"Mycoses"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1542\/peds.2011-0279","article-title":"Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: A randomized controlled trial","volume":"129","author":"Manzoni","year":"2012","journal-title":"Pediatrics"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00431-013-2041-4","article-title":"Prophylactic Saccharomyces boulardii versus nystatin for the prevention of fungal colonization and invasive fungal infection in premature infants","volume":"172","author":"Demirel","year":"2013","journal-title":"Eur. J. Pediatr."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.clnu.2013.05.009","article-title":"Prebiotic supplementation in preterm neonates: Updated systematic review and meta-analysis of randomised controlled trials","volume":"32","author":"Srinivasjois","year":"2013","journal-title":"Clin. Nutr."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1586\/14787210.2013.811925","article-title":"Invasive fungal infections in newborns and current management strategies","volume":"11","author":"Hundalani","year":"2013","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1517\/14656566.6.10.1647","article-title":"Neonatal candidiasis: Prophylaxis and treatment","volume":"6","author":"Tiffany","year":"2005","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1185\/03007995.2010.487799","article-title":"Challenging issues in neonatal candidiasis","volume":"26","author":"Kaufman","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1056\/NEJMoa010494","article-title":"Fluconazole prophylaxis against fungal colonization and infection in preterm infants","volume":"345","author":"Kaufman","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.earlhumdev.2011.01.013","article-title":"Antifungal prophylaxis in neonates","volume":"87","author":"Manzoni","year":"2011","journal-title":"Early Hum. Dev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1542\/peds.2007-1130","article-title":"Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species","volume":"121","author":"Healy","year":"2008","journal-title":"Pediatrics"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1001\/jama.2014.2624","article-title":"Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: A randomized clinical trial","volume":"311","author":"Benjamin","year":"2014","journal-title":"JAMA"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/cid\/ciw363","article-title":"Fluconazole Prophylaxis for the Prevention of Candidiasis in Premature Infants: A Meta-analysis Using Patient-level Data","volume":"63","author":"Ericson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jpeds.2010.11.002","article-title":"Fluconazole prophylaxis in extremely low birth weight infants and neurodevelopmental outcomes and quality of life at 8 to 10 years of age","volume":"158","author":"Kaufman","year":"2011","journal-title":"J. Pediatr."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"F164","DOI":"10.1136\/adc.2009.178996","article-title":"Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low birth weight infants","volume":"96","author":"Aydemir","year":"2011","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/s-0029-1224871","article-title":"Comparison of fluconazole and nystatin oral suspensions for prophylaxis of systemic fungal infection in very low birthweight infants","volume":"27","author":"Violaris","year":"2010","journal-title":"Am. J. Perinatol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Austin, N., Darlow, B.A., and McGuire, W. (2013). Prophylactic oral\/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD003478.pub4"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/bcp.12025","article-title":"Antifungal agents and therapy for infants and children with invasive fungal infections: A pharmacological perspective","volume":"75","author":"Lestner","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Fortmann, I., Hartz, A., Paul, P., Pulzer, F., Muller, A., Bottger, R., Proquitte, H., Dawczynski, K., Simon, A., and Rupp, J. (2018). Antifungal Treatment and Outcome in Very-Low-Birth-Weight-Infants\u2014A Population-Based Observational Study of the German Neonatal Network. Pediatr. Infect. Dis. J.","DOI":"10.1097\/INF.0000000000002001"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.jinf.2014.07.012","article-title":"Neonatal candidiasis: Diagnosis, prevention, and treatment","volume":"69","author":"Greenberg","year":"2014","journal-title":"J. Infect."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jpeds.2012.01.053","article-title":"Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis","volume":"161","author":"Greenberg","year":"2012","journal-title":"J. Pediatr."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1439-0507.2005.01183.x","article-title":"Candida endocarditis in neonates: Report of five cases and review of the literature","volume":"49","author":"Levy","year":"2006","journal-title":"Mycoses"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/myc.12664","article-title":"Performance of 1,3-\u03b2-d-glucan for diagnosing invasive fungal diseases in children","volume":"60","author":"Calitri","year":"2017","journal-title":"Mycoses"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/14767058.2012.722716","article-title":"(1-3)-\u03b2-d-glucan levels in candidiasis infections in the critically ill neonate","volume":"26","author":"Goudjil","year":"2013","journal-title":"J. Matern. Fetal Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/mmy\/myx021","article-title":"Evaluation of the (1,3)-\u03b2-d-glucan assay for the diagnosis of neonatal invasive yeast infections","volume":"56","author":"Cornu","year":"2018","journal-title":"Med. Mycol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1128\/JCM.00496-17","article-title":"Performance of a Quantitative PCR-Based Assay and \u03b2-d-Glucan Detection for Diagnosis of Invasive Candidiasis in Very-Low-Birth-Weight Preterm Neonatal Patients (CANDINEO Study)","volume":"55","author":"Ramos","year":"2017","journal-title":"J. Clin. Microbiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1093\/ajcp\/aqw063","article-title":"T2Candida Provides Rapid and Accurate Species Identification in Pediatric Cases of Candidemia","volume":"145","author":"Hamula","year":"2016","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0022-3476(05)82674-5","article-title":"Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates","volume":"116","author":"Baley","year":"1990","journal-title":"J. Pediatr."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1055\/s-2003-40008","article-title":"Neonatal invasive candidiasis: A prospective multicenter study of 118 cases","volume":"20","year":"2003","journal-title":"Am. J. Perinatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1442-200x.2005.02135.x","article-title":"The efficacy of two different lipid-based amphotericin B in neonatal Candida septicemia","volume":"47","author":"Cetin","year":"2005","journal-title":"Pediatr. Int."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3349\/ymj.2007.48.4.619","article-title":"A comparison of AmBisome to amphotericin B for treatment of systemic candidiasis in very low birth weight infants","volume":"48","author":"Jeon","year":"2007","journal-title":"Yonsei Med. J."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.diagmicrobio.2015.04.008","article-title":"Isavuconazole, micafungin, and 8 comparator antifungal agents\u2019 susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: Temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values","volume":"82","author":"Pfaller","year":"2015","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2147\/IDR.S118892","article-title":"Fluconazole resistance in Candida species: A current perspective","volume":"10","author":"Berkow","year":"2017","journal-title":"Infect. Drug Resist."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1093\/jpids\/piy009","article-title":"Neonatal and Pediatric Candidemia: Results From Population-Based Active Laboratory Surveillance in Four US Locations, 2009\u20132015","volume":"7","author":"Benedict","year":"2018","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"7901763","DOI":"10.1155\/2017\/7901763","article-title":"Candidemia in the Neonatal Intensive Care Unit: A Retrospective, Observational Survey and Analysis of Literature Data","volume":"2017","author":"Caggiano","year":"2017","journal-title":"BioMed Res. Int."},{"key":"ref_92","unstructured":"Warris, A., Pana, Z.D., Oletto, A.R.L., Roilides, E., and EUROCANDY Study Group (June, January 28). Antifungal drug susceptibility of candida spp. in neonatal and paediatric candidaemia: A european multi-centre retrospective study (EUROCANDY). Proceedings of the 36th Annual Meeting of The European Society For Pediatric Infectious Diseases ESPID 2018, Malm\u00f6, Sweden."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/INF.0000000000001996","article-title":"A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis","volume":"37","author":"Benjamin","year":"2018","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1128\/AAC.01172-16","article-title":"High-Dose Micafungin for Preterm Neonates and Infants with Invasive and Central Nervous System Candidiasis","volume":"60","author":"Auriti","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1345\/aph.1Q346","article-title":"Echinocandin use in the neonatal intensive care unit","volume":"46","author":"Caudle","year":"2012","journal-title":"Ann. Pharmacother."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1128\/AAC.02085-12","article-title":"Favorable outcome of neonatal cerebrospinal fluid shunt-associated Candida meningitis with caspofungin","volume":"57","author":"Jans","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1128\/AAC.05826-11","article-title":"Anidulafungin for neonatal hematogenous Candida meningoencephalitis: Identification of candidate regimens for humans using a translational pharmacological approach","volume":"56","author":"Warn","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4137\/CMPed.S8028","article-title":"Invasive fungal infections in infants-focus on anidulafungin","volume":"7","author":"Wilke","year":"2013","journal-title":"Clin. Med. Insights Pediatr."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/clpt.2011.26","article-title":"Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates","volume":"89","author":"Benjamin","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1038\/bjc.2012.147","article-title":"Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: A systematic review and meta-analysis of randomised controlled trials","volume":"106","author":"Ethier","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/pds.1073","article-title":"Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions","volume":"14","author":"Yu","year":"2005","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Gastine, S., Lehrnbecher, T., Muller, C., Farowski, F., Bader, P., Ullmann-Moskovits, J., Cornely, O.A., Groll, A.H., and Hempel, G. (2018). Pharmacokinetic Modeling of Voriconazole to Develop an Alternative Dosing Regimen in Children. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.01194-17"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/pbc.22972","article-title":"Risk of azole-enhanced vincristine neurotoxicity in pediatric patients with hematological malignancies: Old problem\u2014new dilemma","volume":"57","author":"Pana","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/MPH.0000000000000926","article-title":"Voriconazole Antifungal Prophylaxis in Children With Malignancies: A Nationwide Study","volume":"40","author":"Pana","year":"2018","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/bcp.13401","article-title":"Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children","volume":"84","author":"Allegra","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Doring, M., Muller, C., Johann, P.D., Erbacher, A., Kimmig, A., Schwarze, C.P., Lang, P., Handgretinger, R., and Muller, I. (2012). Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. BMC Infect. Dis., 12.","DOI":"10.1186\/1471-2334-12-263"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10096-013-1998-2","article-title":"Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation","volume":"33","author":"Doring","year":"2014","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s10096-015-2340-y","article-title":"Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia","volume":"34","author":"Doring","year":"2015","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJM200309183491220","article-title":"Preventing fungal infections in chronic granulomatous disease","volume":"349","author":"Verweij","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/INF.0b013e3182195808","article-title":"A twice daily posaconazole dosing algorithm for children with chronic granulomatous disease","volume":"30","author":"Welzen","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00520-016-3412-y","article-title":"Critical review of current clinical practice guidelines for antifungal therapy in paediatric haematology and oncology","volume":"25","author":"Morgan","year":"2017","journal-title":"Support. Care Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1093\/jac\/dky244","article-title":"Efficacy of pre-emptive versus empirical antifungal therapy in children with cancer and high-risk febrile neutropenia: A randomized clinical trial","volume":"73","author":"Santolaya","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/INF.0b013e3181da2171","article-title":"A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia","volume":"29","author":"Maertens","year":"2010","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Cortegiani, A., Russotto, V., Maggiore, A., Attanasio, M., Naro, A.R., Raineri, S.M., and Giarratano, A. (2016). Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD004920.pub3"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1093\/jpids\/pix054","article-title":"Role of Molecular Biomarkers in the Diagnosis of Invasive Fungal Diseases in Children","volume":"6","author":"Huppler","year":"2017","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/cid\/ciw592","article-title":"Galactomannan, \u03b2-d-Glucan, and Polymerase Chain Reaction-Based Assays for the Diagnosis of Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis","volume":"63","author":"Lehrnbecher","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/myc.12584","article-title":"Comparative evaluation of pan-fungal real-time PCR, galactomannan and (1-3)-\u03b2-d-glucan assay for invasive fungal infection in paediatric cancer patients","volume":"60","author":"Gupta","year":"2017","journal-title":"Mycoses"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2217\/fmb-2018-0079","article-title":"Use of T2MR in invasive candidiasis with and without candidemia","volume":"13","author":"Zacharioudakis","year":"2018","journal-title":"Future Microbiol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1128\/AAC.04109-14","article-title":"Systemic antifungal prescribing in neonates and children: Outcomes from the Antibiotic Resistance and Prescribing in European Children (ARPEC) Study","volume":"59","author":"Lestner","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1542\/peds.2008-1158","article-title":"A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients","volume":"123","author":"Zaoutis","year":"2009","journal-title":"Pediatrics"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/423381","article-title":"Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy","volume":"39","author":"Maertens","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_123","first-page":"305","article-title":"Efficacy and safety of caspofungin in children: Systematic review and meta-analysis","volume":"114","author":"Rosanova","year":"2016","journal-title":"Arch. Argent. Pediatr."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1097\/INF.0b013e31829efd14","article-title":"Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis","volume":"32","author":"Benjamin","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/INF.0b013e31817275e6","article-title":"Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: Substudy of a randomized double-blind trial","volume":"27","author":"Berezin","year":"2008","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Lee, C.H., Lin, J.C., Ho, C.L., Sun, M., Yen, W.T., and Lin, C. (2017). Efficacy and safety of micafungin versus extensive azoles in the prevention and treatment of invasive fungal infections for neutropenia patients with hematological malignancies: A meta-analysis of randomized controlled trials. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0180050"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Tsekoura, M., Ioannidou, M., Pana, Z.D., Haidich, A.B., Antachopoulos, C., Iosifidis, E., Kolios, G., and Roilides, E. (2018). Efficacy and Safety of Echinocandins for the Treatment of Invasive Candidiasis in Children: A Meta-Analysis. Pediatr. Infect. Dis. J.","DOI":"10.1097\/INF.0000000000002032"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1128\/AAC.50.2.632-638.2006","article-title":"Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections","volume":"50","author":"Benjamin","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_129","first-page":"374","article-title":"Anidulafungin in children: Experience in a tertiary care children\u2019s hospital in Argentina","volume":"115","author":"Rosanova","year":"2017","journal-title":"Arch. Argent. Pediatr."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Roilides, E., Carlesse, F., Leister-Tebbe, H., Conte, U., Yan, J.L., Liu, P., Tawadrous, M., Aram, J.A., Queiroz-Telles, F., and on behalf of the anidulafungin A8851008 pediatric study group (2018). A Prospective, Open-label Study to Assess the Safety, Tolerability, and Efficacy of Anidulafungin in the Treatment of Invasive Candidiasis in Children Aged 2 to <18 Years Old. Pediatr. Infect. Dis. J., in press.","DOI":"10.1097\/INF.0000000000002237"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Pana, Z.D., Seidel, D., Skiada, A., Groll, A.H., Petrikkos, G., Cornely, O.A., Roilides, E., and Collaborators of Zygomyco.net and\/or FungiScope Registries (2016). Invasive mucormycosis in children: An epidemiologic study in European and non-European countries based on two registries. BMC Infect. Dis., 16.","DOI":"10.1186\/s12879-016-2005-1"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s10096-010-0957-4","article-title":"Posaconazole salvage treatment in paediatric patients: A multicentre survey","volume":"29","author":"Lehrnbecher","year":"2010","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3109\/1040841X.2012.711741","article-title":"Mucormycosis treated with posaconazole: Review of 96 case reports","volume":"39","author":"Vehreschild","year":"2013","journal-title":"Crit. Rev. Microbiol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1469-0691.12371","article-title":"ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013","volume":"20","author":"Cornely","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1128\/AAC.00454-06","article-title":"Posaconazole plasma concentrations in juvenile patients with invasive fungal infection","volume":"51","author":"Krishna","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/ejh.13017","article-title":"Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients","volume":"100","author":"Vicenzi","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent","volume":"61","author":"Miceli","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e27281","DOI":"10.1002\/pbc.27281","article-title":"Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients","volume":"65","author":"Barg","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12281-014-0175-0","article-title":"Rare Fungal Infections in Children: An Updated Review of the Literature","volume":"8","author":"Pana","year":"2014","journal-title":"Curr. Fungal Infect. Rep."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1469-0691.2011.03689.x","article-title":"Immunotherapy of infections caused by rare filamentous fungi","volume":"18","author":"Katragkou","year":"2012","journal-title":"Clin. Microbiol. Infect."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/4\/4\/115\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:25:07Z","timestamp":1760196307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/4\/4\/115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,11]]},"references-count":140,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["jof4040115"],"URL":"https:\/\/doi.org\/10.3390\/jof4040115","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,11]]}}}